Why Are Chinook Therapeutics Shares Trading Higher Today
Portfolio Pulse from Vandana Singh
Novartis AG has agreed to acquire Chinook Therapeutics for $40 per share in cash, totaling $3.2 billion. Chinook shareholders will also receive contingent value rights, providing for payment of up to $4 per share upon achieving certain regulatory milestones for atrasentan. The total consideration would be approximately $3.5 billion.
June 12, 2023 | 11:35 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Chinook Therapeutics shares are trading higher after Novartis AG agreed to acquire the company for $40 per share in cash, totaling $3.2 billion.
Chinook Therapeutics shares are trading higher due to the acquisition announcement by Novartis AG. The offer represents a significant premium to Chinook's stock price, which is a positive development for shareholders.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100
NEGATIVE IMPACT
Novartis AG shares are down slightly after announcing the acquisition of Chinook Therapeutics for $40 per share in cash, totaling $3.2 billion.
Novartis AG shares are down slightly as the company announced the acquisition of Chinook Therapeutics. The acquisition will have a short-term impact on the company's cash reserves, which may cause some investors to be cautious.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100